1 July 2016

Timis scoops £80m

Robert Tyerman

Frank Timis, executive chairman of African Minerals, has secured an £80m fundraising

Frank Timis, executive chairman of African Minerals, has secured an £80m fundraising

Frank Timis’s African Minerals has raised £80 million at £4 for its Tonkolili iron ore project in Sierra Leone.

The AIM-quoted company has secured the funding in an underwritten institutional placing, with the help of Canaccord Adams and Mirabaud Securities, to start infrastructure building at Tonkolili. African Minerals hopes to double a currently estimated resource of 5.1 billion tonnes there to 10 billion tonnes and to start production early next year.

The placing proceeds will go to build a 120 km haul road from the mine site at Tonkolili to the nearest railhead and to refurbish rail and port facilities. In addition, African Minerals has granted options to subscribe for £11.5 million-worth of shares at the placing price to China Railways Materials Commercial Corporation, with which the company already has a supply agreement.

Timis, the controversial former boss of Regal Petroleum and owner of 33.5 per cent of African Minerals, declares that the funding and off-take deals struck for Tonkolili’s output ‘place the company in a very strong position to realise iron ore production from Tonkolili during the first quarter of 2011’.

Floated at 75p three years ago, African Minerals’ shares, which dipped to 20p at one point, have recently been star performers, hitting a 440p high, and now trade at 399.75p, valuing the company at £854 million.

Tags: AIM, Deals & contracts, Fundraisings

Cash Shells 2015

Published in September 2015 this annual research report provides a comprehensive overview of cash shells on the Main Market, AIM and PLUS landscape. Order your copy today

 

Superb investment toolkit for private investors

SharePad is the new web-based service from ShareScope. Easier to use and more powerful. Perfect for tablets, Macs and Windows PC. Covers ALL your investment requirements.

Growth Company Investor: free trial

Since 2008, our share tips outperformed the benchmark by 281%. Take a free trial and get access to our recommendations today. Start free trial now.

Directors' Pay on AIM 2015

The most comprehensive review of AIM directors' pay available, and this year includes a record sample of 1000+ AIM-quoted companies. The full report is available to order for £385 + VAT. Click here for more info

 

Latest small-cap and growth company news

Daily coverage of small-cap company stocks on London's junior markets AIM and PLUS, breaking news, stock research and latest share price information for investors. Full sector coverage with all the latest news on smaller listed companies, updated several times a day with financial reports, trading statements and links to further web resources.

Popular News

Latest News

The robots are coming

Recent AIM newcomer Blue Prism (AIM: PRSM) has released a promising set of maiden results for the half year to April. Revenues grew by a handy 21 per cent and momentum seems to be accelerating with 33 new customers added to the 57 in place at the end of October. 

Avingtrans returns cash and remains a Buy

Having turned most of its market cap into cash through the sale of its aerospace division, it’s no surprise that Avingtrans (AIM: AVG) has been a very defensive stock during the recent turmoil. We now have some more details on the return of cash to shareholders which was promised as part of the disposal.

Omega investing in growth

Omega Diagnostics results looked positive and highlighted the progress being made in getting important new products to market. The investment to support those efforts will depress profits this year; but the market seems willing to look through this with Omega being a rare stock to be trading above its pre-Brexit level.

Stadium hit by profit warning

Stadium Group shares have been hit by a profit warning. This is a particular blow given the company’s progress in repositioning itself into a higher quality, design-led business.

Verona raises £42m to fund drug trials 

Verona Pharma (AIM: VRP) has raised an impressive £42 million net of costs which will fund phase II trials for its RPL554 compound. This drug targets severe respiratory diseases, in particular the 65 million worldwide sufferers from COPD (chronic obstructive pulmonary disease).

Income attractions at Belvoir

It’s fair to say that buy-to-let landlords have been under George Osborne’s cosh. He’s introduced a raised stamp duty rate and withdrawn higher-rate tax relief. However, Belvoir Lettings has seen little change in the market as far as its core lettings agency business is concerned. Furthermore, the shares have responded positively to a major acquisition which makes Belvoir the largest UK lettings agent.

More News